Zio­pharm finds new CEO af­ter six-month search; CFO tran­si­tion at Lon­za to take place in De­cem­ber

Less than a year re­moved from a suc­cess­ful ac­tivist at­tack, Zio­pharm On­col­o­gy ap­point­ed a new CEO this week. Tak­ing the reins will be Kevin Boyle, who comes over af­ter lead­ing Ku­ur Ther­a­peu­tics to a $185 mil­lion buy­out back in May.

It’s been a tough few years for Zio­pharm, which in ad­di­tion to tak­ing on the with­er­ing ac­tivist at­tack saw sig­nif­i­cant turnover at the C-suite lev­el, cul­mi­nat­ing in long­time CEO Lau­rence Coop­er hit­ting the ex­it in Feb­ru­ary. That kicked off a near­ly half-year search that has now found Boyle set to take charge.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA